Precigen, Inc. (NYSE:PGEN) Expected to Post Earnings of -$0.14 Per Share

Brokerages expect Precigen, Inc. (NYSE:PGEN – Get Rating) to announce earnings per share of ($0.14) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Precigen’s earnings. The highest EPS estimate is ($0.13) and the lowest is ($0.15). Precigen reported earnings of ($0.11) per share in the same quarter last year, which would suggest a negative year over year growth rate of 27.3%. The firm is scheduled to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Precigen will report full year earnings of ($0.43) per share for the current year, with EPS estimates ranging from ($0.55) to ($0.25). For the next financial year, analysts anticipate that the business will post earnings of ($0.62) per share, with EPS estimates ranging from ($0.76) to ($0.53). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that cover Precigen.

Separately, StockNews.com started coverage on Precigen in a research note on Thursday, March 31st. They set a “sell” rating for the company.

Shares of NYSE:PGEN traded down $0.02 during trading on Monday, reaching $1.59. The stock had a trading volume of 40,359 shares, compared to its average volume of 1,719,740. Precigen has a 52 week low of $1.44 and a 52 week high of $8.72.

About Precigen (Get Rating)

Precigen, Inc discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L.

Featured Stories